Published: 6 September 2016
Author(s): Francisco José Fernández-Fernández
Section: Letter to the Editor

I read with interest the article “Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis” by Rokkas and Portincasa [1]. As the authors note, the mechanisms underlying the antineoplastic potential of metformin in colon neoplasia are probably manifold and not yet completely understood. Experimental data support a direct effect of metformin in antagonizing specific pathways that promote cell proliferation, motility, invasion, and migration. As Rokkas and Portincasa mention, metformin activates AMP-activated protein kinase (AMPK), leading to downregulation of the mTOR pathway that is crucial to tumor cell metabolism.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.